Bitcoin miners have increased selling activity, sending nearly 20,000 BTC to exchanges as prices recover toward $85,000, helping them cover operational costs. However, the impact on Bitcoin’s price depends on how miners use proceeds from sales. Meanwhile, miners are diversifying revenue by leveraging AI and high-power computing, which offer higher returns than traditional mining. This shift could slow Bitcoin hashrate growth and reduce miners' reliance on Bitcoin mining alone, potentially stabilizing their income despite Bitcoin price fluctuations.
Bitcoin miners' pivot to AI and increased selling activity come as 43 of 50 major cryptocurrencies on Pluang rose today. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 25, 2026 01:32 WIB: Litecoin gained 19.51% to Rp1.288.690 with a typical hold time of 78 days and 60% sell order activity; Ethereum Classic rose 14.24% to Rp177.525 with 77% sell orders; Harmony fell 16.93% to Rp44 with a balanced buy/sell split. This breadth indicates strong overall market movement despite some declines.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
